New biomarkers for lung cancer

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Importance of the field: Despite many efforts to improve early detection, lung cancer remains the leading cause of cancer deaths. Stage is the main determinant of prognosis and the basis for deciding treatment options. Screening tests for lung cancer have not been successful so far. Areas covered in the review: The article reviews the available literature related to biomarkers in use at present and those that could be used for early diagnosis, staging, prognosis, response to therapy and prediction of recurrence. The single biomarkers are analysed, divided according to the technological methods used and the locations of sampling. What the reader will gain: The reader will gain knowledge on biomarkers in use and those now under study. The reader will also gain insights into the difficulties pertaining to the development of biomarkers, results reproducibility and clinical application. Take home message: Although some markers seem to be promising, at present there is no consensus on the proven value of their clinical use in lung cancer. The future lies probably in a panel of biomarkers instead of individual assays, or in predictive models derived from the integration of clinical variables and gene expression profiles.

Original languageEnglish
Pages (from-to)201-224
Number of pages24
JournalExpert Opinion on Medical Diagnostics
Volume4
Issue number3
DOIs
Publication statusPublished - May 2010

Fingerprint

Biomarkers
Lung Neoplasms
Early Detection of Cancer
Transcriptome
Gene expression
Reproducibility of Results
Early Diagnosis
Cause of Death
Assays
Screening
Sampling
Recurrence
Neoplasms

Keywords

  • Early detection
  • Genomics
  • Lung cancer
  • Metabolomics
  • Molecular biomarkers
  • Prognosis
  • Proteomics
  • Screening

ASJC Scopus subject areas

  • Biomedical Engineering
  • Medicine(all)
  • Biochemistry, medical
  • Molecular Medicine

Cite this

New biomarkers for lung cancer. / Paci, Massimiliano; Rapicetta, Cristian; Maramotti, Sally.

In: Expert Opinion on Medical Diagnostics, Vol. 4, No. 3, 05.2010, p. 201-224.

Research output: Contribution to journalArticle

@article{5340cc13c3f14a77aa1daf5feab325a7,
title = "New biomarkers for lung cancer",
abstract = "Importance of the field: Despite many efforts to improve early detection, lung cancer remains the leading cause of cancer deaths. Stage is the main determinant of prognosis and the basis for deciding treatment options. Screening tests for lung cancer have not been successful so far. Areas covered in the review: The article reviews the available literature related to biomarkers in use at present and those that could be used for early diagnosis, staging, prognosis, response to therapy and prediction of recurrence. The single biomarkers are analysed, divided according to the technological methods used and the locations of sampling. What the reader will gain: The reader will gain knowledge on biomarkers in use and those now under study. The reader will also gain insights into the difficulties pertaining to the development of biomarkers, results reproducibility and clinical application. Take home message: Although some markers seem to be promising, at present there is no consensus on the proven value of their clinical use in lung cancer. The future lies probably in a panel of biomarkers instead of individual assays, or in predictive models derived from the integration of clinical variables and gene expression profiles.",
keywords = "Early detection, Genomics, Lung cancer, Metabolomics, Molecular biomarkers, Prognosis, Proteomics, Screening",
author = "Massimiliano Paci and Cristian Rapicetta and Sally Maramotti",
year = "2010",
month = "5",
doi = "10.1517/17530051003725113",
language = "English",
volume = "4",
pages = "201--224",
journal = "Expert Opinion on Medical Diagnostics",
issn = "1753-0059",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - New biomarkers for lung cancer

AU - Paci, Massimiliano

AU - Rapicetta, Cristian

AU - Maramotti, Sally

PY - 2010/5

Y1 - 2010/5

N2 - Importance of the field: Despite many efforts to improve early detection, lung cancer remains the leading cause of cancer deaths. Stage is the main determinant of prognosis and the basis for deciding treatment options. Screening tests for lung cancer have not been successful so far. Areas covered in the review: The article reviews the available literature related to biomarkers in use at present and those that could be used for early diagnosis, staging, prognosis, response to therapy and prediction of recurrence. The single biomarkers are analysed, divided according to the technological methods used and the locations of sampling. What the reader will gain: The reader will gain knowledge on biomarkers in use and those now under study. The reader will also gain insights into the difficulties pertaining to the development of biomarkers, results reproducibility and clinical application. Take home message: Although some markers seem to be promising, at present there is no consensus on the proven value of their clinical use in lung cancer. The future lies probably in a panel of biomarkers instead of individual assays, or in predictive models derived from the integration of clinical variables and gene expression profiles.

AB - Importance of the field: Despite many efforts to improve early detection, lung cancer remains the leading cause of cancer deaths. Stage is the main determinant of prognosis and the basis for deciding treatment options. Screening tests for lung cancer have not been successful so far. Areas covered in the review: The article reviews the available literature related to biomarkers in use at present and those that could be used for early diagnosis, staging, prognosis, response to therapy and prediction of recurrence. The single biomarkers are analysed, divided according to the technological methods used and the locations of sampling. What the reader will gain: The reader will gain knowledge on biomarkers in use and those now under study. The reader will also gain insights into the difficulties pertaining to the development of biomarkers, results reproducibility and clinical application. Take home message: Although some markers seem to be promising, at present there is no consensus on the proven value of their clinical use in lung cancer. The future lies probably in a panel of biomarkers instead of individual assays, or in predictive models derived from the integration of clinical variables and gene expression profiles.

KW - Early detection

KW - Genomics

KW - Lung cancer

KW - Metabolomics

KW - Molecular biomarkers

KW - Prognosis

KW - Proteomics

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=77953772723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953772723&partnerID=8YFLogxK

U2 - 10.1517/17530051003725113

DO - 10.1517/17530051003725113

M3 - Article

C2 - 23488531

AN - SCOPUS:77953772723

VL - 4

SP - 201

EP - 224

JO - Expert Opinion on Medical Diagnostics

JF - Expert Opinion on Medical Diagnostics

SN - 1753-0059

IS - 3

ER -